SCHEMBL689712

SCHEMBL689712

COc1c(N)cc(C(C)(C)C)cc1NS(C)(=O)=O

nearest known ligand 0.51

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.51
SCARB1 Q8WTV0 5/20 0.41
BRAF P15056 1/20 0.38
GSK3A P49840 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1301953 0.98 MAPK14 (0.50) MAPK14SCARB1BRAFGSK3A
SCHEMBL19434662 0.90 MAPK14 (0.44) MAPK14SCARB1BRAF
SCHEMBL1936083 0.87 MAPK14 (0.40) MAPK14
SCHEMBL17545234 0.85 HPGD (0.42) MAPK14SCARB1
SCHEMBL2670913 0.85 MAPK14 (0.40) MAPK14SCARB1GSK3A
SCHEMBL10104416 0.84 MAPK14 (0.53) MAPK14SCARB1BRAF
SCHEMBL689355 0.84 MAPK14 (0.41) MAPK14SCARB1
SCHEMBL16106595 0.84 MAPK14 (0.39) MAPK14SCARB1GSK3A
SCHEMBL1935707 0.84 MAPK14 (0.39) MAPK14SCARB1
SCHEMBL16106484 0.84 CA2 (0.40) MAPK14GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323980-B1 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INT (DE) 2012-02-29 EP claimed
EP-1670787-A4 CYTOKINE INHIBITORS KEMIA INC (US) 2009-04-22 EP claimed
US-7335657-B2 Cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-02-26 US claimed
US-20060235017-A1 Cytokine Inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-10-19 US claimed
US-7078419-B2 N-aryl-7-(pyridin-4yl-methyl-, oxy-, thio-or amino-)indole-2-carbonamide derivatives, e.g., 7-(2,6-Dimethyl-pyridin-4-yloxy)-1H-indole-2-carboxylic acid (5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide; treating chronic inflammatory diseases and anticoagulant or fibrinolytic therapy BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-07-18 US claimed
EP-1670787-A2 CYTOKINE INHIBITORS Kemia, INC. (US) 2006-06-21 EP claimed
EP-1631567-A2 HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-03-08 EP claimed
US-20050107399-A1 Cytokine inhibitors KEMIA, INC. 2005-05-19 US claimed
WO-2005023761-A2 CYTOKINE INHIBITORS KEMIA, INC. (US) 2005-03-17 WO claimed
WO-2005016918-A2 HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-02-24 WO claimed
EP-3440073-B1 KINASE INHIBITORS OXULAR ACQUISITIONS LTD (GB) 2022-06-08 EP disclosed
CN-109071505-B Kinase inhibitors 奥苏拉收购有限公司 2021-11-16 CN disclosed
EP-2981526-B1 INTERMEDIATES USEFUL IN THE PREPARATION OF NAPHTHYLUREA DERIVATIVES USEFUL AS KINASE INHIBITORS OXULAR ACQUISITIONS LTD (GB) 2021-11-03 EP disclosed
EP-2981526-B1 INTERMEDIATES USEFUL IN THE PREPARATION OF NAPHTHYLUREA DERIVATIVES USEFUL AS KINASE INHIBITORS OXULAR ACQUISITIONS LTD (GB) 2021-11-03 EP disclosed
US-10941115-B2 Kinase inhibitors OXULAR ACQUISITIONS LIMITED (GB) 2021-03-09 US disclosed
US-20030008868-A1 Compounds useful as anti-inflammatory agents BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-01-09 US disclosed
WO-2002092576-A1 DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-11-21 WO disclosed
WO-2002083642-A1 COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-10-24 WO disclosed
WO-2002083628-A1 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-10-24 WO disclosed
US-20020032195-A1 Compounds useful as anti-inflammatory agents BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107399-A1 Cytokine inhibitors TNF, IL1RN, IL1A MAPK14 371/4885SCARB1 425/4885BRAF 3313/4885
US-20020032195-A1 Compounds useful as anti-inflammatory agents MPO, EPX, PTGES MAPK14 3499/4885SCARB1 324/4885BRAF 4069/4885
US-20030008868-A1 Compounds useful as anti-inflammatory agents TNF, MPO, PTGES MAPK14 2714/4885SCARB1 364/4885BRAF 4411/4885
US-10941115-B2 Kinase inhibitors SYK, LYN, BTK MAPK14 118/4885SCARB1 786/4885BRAF 109/4885
US-20060235017-A1 Cytokine Inhibitors IL1B, IL1A, IL1R1 MAPK14 2628/4885SCARB1 425/4885BRAF 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.